Abstract:Acquired hemophilia A (AHA) is anunusual disease resulting from autoantibodies (inhibitors) against coagulation factor VIII (FVIII) and clinically manifests as bleeding, which sometimes can cause potentially limb-threatening or life-threatening situations. AHA is associated with cancers, auto-immune disorders, infections, dermatologic conditions and certain medications, among which it is commonly secondary to multiple rheumatologic conditions, such as rheumatoid arthritis, systemic lupus erythematosus (SLE), pollymyositis, autoimmune hemolytic anemia and undifferentiated connective tissue disease. In autoimmune diseases, it may be the result of autoantibody producing against FVIII, and some cases of AHA may act as the first manifestation of SLE. AHA should be suspected in patients who have spontaneously hemorrhagic events with an isolated prolonged activated partial thromboplastin time (APTT), reduced FVIII activity and a negative lupus anticoagulant (LA). When FVIII inhibitor is found, it can be diagnosed. The management of AHA focuses on the following goals: (1) controlling and preventing bleeding, (2) eradication of the inhibitor, (3) treatment of the underlying disease. Here, a case of AHA in a patient with lupus is reported. A 53-year-old man with a 4-year history of SLE developed arthralgia and ecchymotic skin lesions after arthrocentesis of knee joint. Ultrasound confirmed the presence of an intramuscular hematoma. Coagulation tests revealed that FVIII activity reduced to 1% and a prolonged APTT (92.2 s), FVIII inhibitors were found to be as high as 60.0 Bethesda Units. Initial treatments with methylprednisolone 200 mg/d were started but new hemorrhagic manifestation occurred and hisbiological indexes were not good. Then the patient was treated with intravenous pulse corticosteroids (methylprednisolone 500 mg/d), intravenous cyclophosphamide, and also plasma and prothrombin complex infusion. Subsequently, FVIII activity returned within normal ranges, FVIII inhibitors decreased and clinical improvement was significantly obtained. The patient's condition kept stable till now.Hemorrhagic events due to production of antibodies directed against coagulation factors were rarely observed in SLE and attentions should be paid to the association between SLE and AHA.Bypass treatment was considered as the immediate antihemorrhagic treatment. Corticosteroid combined with immunosuppressor was recommended as the main therapy to eradicate the inhibitors. However we still lack the therapeutic guidelines and standardized treatment in patients of AHA with SLE at present.

Inhibitor eradication and treatment for acquired hemophilia A

Innovative Therapies for Acquired Hemophilia A

Acquired hemophilia A as a disease of the elderly: A comprehensive review of epidemiology, pathogenesis, and novel therapy

Acquired hemophilia A: a single-center study of 165 patients

Diagnosis and laboratory monitoring of hemophilia A

Inhibitor Eradication and Bleeding Management of Acquired Hemophilia A: a Single Center Experience in China

Recognition of the unique bleeding pattern and laboratory findings in acquired haemophilia A facilitates prompt treatment of a life-threatening disorder

[Acquired hemophilia A associated with bullous pemphigoid and multiple myeloma: a case report]

Postpartum Acquired Hemophilia A

[Systemic Lupus Erythematosus with Acquired Hemophilia A: a Case Report].

Acquired Hemophilia A Patients: Clinical Experience of 12 Cases

Acquired Hemophilia A Diagnosed Based on Gross Hematuria: A Case Report and Literature Review

A Rare Case of Hemophilia: Acquired Factor VIII Deficiency

Acquired hemophilia A in a woman with systemic lupus erythematosus: A case report and review of literature

Comprehensive evaluation of anti-emicizumab antibodies in acquired hemophilia A: a detailed case study and methodological evaluation

Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients

S3627 Acquired Hemophilia A as a Cause of Obscure Gastrointestinal Bleeding

Acquired haemophilia A in paediatric patients: A retrospective French cohort of eight cases

Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A

Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort

A Rare Case of Acquired Factor VIII Deficiency in an Elderly Male With a History of Rheumatoid Arthritis